Table 4.
Treatment of 186 hospitalized patients with acute respiratory illness and tested for COVID-19.
| COVID-19 positive (n = 26) | COVID-19 negative (n = 160) | P value | |
|---|---|---|---|
| Antibiotics administered | 17/26 (65%) | 134/160 (84%) | 0.054 |
| Vancomycin | 8/26 (31%) | 72/160 (45%) | 0.126 |
| Piperacillin/tazobactam | 5/26 (19%) | 55/160 (35%) | 0.107 |
| Cefepime | 4/26 (15%) | 17/160 (11%) | 0.504 |
| Ceftriaxone` | 10/26 (39%) | 74/160 (46%) | 0.459 |
| Carbapenems | 3/26 (12%) | 19/160 (12%) | 1.000 |
| Azithromycin | 8/26 (31%) | 44/160 (28%) | 0.731 |
| Doxycycline | 7/26 (29%) | 70/160 (44%) | 0.106 |
| Fluoroquinolones | 4/26 (15%) | 32/160 (20%) | 0.581 |
| Other antibiotics | 4/26 (15%) | 43/160 (27%) | 0.329 |
| Oseltamivir | 3/26 (12%) | 15/160 (9%) | 0.729 |
| Remdesivir clinical trial* | 6/26 (23%) | 0/160 (0%) | <0.001 |
| Chloroquine | 0/26 (0%) | 0/160 (0%) | — |
| Hydroxychloroquine | 6/26 (22%) | 1/160 (<1%) | <0.001 |
| Steroids | 3/26 (12%) | 23/160 (14%) | 1.000 |
| No respiratory support | 6/26 (23%) | 55/160 (34%) | 0.255 |
| Respiratory support | |||
| Supplemental oxygen | 10/20 (50%) | 61/105 (58%) | 0.711 |
| High flow oxygen | 5/20 (25%) | 21/105 (20%) | |
| Noninvasive positive-pressure ventilation or invasive mechanical ventilation | 5/20 (25%) | 23/105 (22%) |
Legend
COVID-19 - Coronavirus Disease 2019.
⁎
Rows are not mutually exclusive, 1 patient received hydroxychloroquine and was enrolled in a blinded remdesivir trial.